Board of Directors

Antony Leung, Chairman


Mr. Antony Leung is the Co-Founder and Group Chairman of New Frontier Group. He also serves as Group Chairman and CEO of Nan Fung Group, a regional conglomerate engaging in real estate and investment businesses. Prior to this, Mr. Leung was Senior Managing Director, Chairman of Greater China and a member of the Executive Committee of Blackstone. He also served as Financial Secretary of Hong Kong from 2001 to 2003 and held numerous leadership positions in financial services including Chairman of Asia for JP Morgan Chase, Country Corporate Officer of Citigroup for China and Hong Kong, Regional Treasurer for North Asia, Head of Investment Banking for North and South West Asia, and Head of Private Banking for Asia.

Carl Wu, President of New Frontier Health


Mr. Carl Wu is the President of New Frontier Group. Mr. Wu is a healthcare and internet entrepreneur. He is the Executive Chairman and Co-founder of YD Care (home healthcare service provider), Heal (oncology group in the Greater Bay area), Boxful Technology (the leading on-demand storage service provider in Asia), HelloToby Technology (the leading online service marketplace in Hong Kong) and Precision Medical. Carl is also the Chairman of Care Alliance (the leading post-acute healthcare operator in China), Chairman of the Executive Committee of New Frontier Health / United Family Healthcare (NYSE: NFH).

Prior to founding New Frontier, Mr. Wu was one of the youngest Managing Directors at Blackstone and executed some of Blackstone’s most important investments in China. He was a founding member of Blackstone Asia and was instrumental in establishing Blackstone’s businesses across China. Prior to moving to Hong Kong, Mr. Wu was based in Blackstone’s London office. Before joining Blackstone, he worked in investment banking at UBS in London.

Mr. Wu holds a Bachelor of Science in Economics from the London School of Economics, where he graduated with First Class Honors.

Roberta Lipson, Executive Director


Ms. Roberta Lipson is the CEO of New Frontier Health and the Founder of New Frontier Health (“UFH”). She founded New Frontier Health (formerly known as Chindex) in 1981 and expanded the business from China’s top medical equipment distribution company into one of China’s first and largest foreign-invested healthcare networks. As CEO, Ms. Lipson leads the development of all UFH operations, helms the organization’s strategic direction, and drives a corporate culture of patient-centered care. Her operational and market initiatives, as well as strategic team-building efforts, are the backbone of UFH’s success.

Ms. Lipson has over 35 years of medical industry experience and has become one of the most recognized healthcare executives in China. She has received several awards for entrepreneurship, leadership, and philanthropy, including the 2002 U.S. Department of State’s Award for Corporate Excellence, the 2009 China Great Wall Friendship Award, the 2014 Pioneer Award from the American Chamber of Commerce, the 2015 “Top Ten Business Leaders of China” award from, the 2016 “Person of the Year” award from CaiXin, the 2017 “Best International Innovator” award from Diyi Caijing, the 2018 Healthcare Asia Magazine “CEO of the Year” award, and the 2019 Asper Award for Global Entrepreneurship from Brandeis University. Ms. Lipson holds a Bachelor of Arts from Brandeis University and an MBA from Columbia University.

Qiyu Chen, Co-Chairman


Mr. Qiyu Chen has been the executive director and the co-president of Fosun International Limited (SEHK: 00656) since July 2015 and March 2017, respectively. In addition, Mr. Chen has also been an executive director and the chairman of Fosun Pharma since May 2005 and May 2010, respectively. Mr. Chen joined Fosun Group in April 1994 and was appointed as a director in May 2005. Mr. Chen also has been a director of Fosun High Tech since July 2015 and the chairman since November 2017. Mr. Chen has served as a non-executive director since May 2010 and a vice chairman since September 2014 of Sinopharm Group Co., Ltd (SEHK: 01099), a non-executive director of Babytree Group (SEHK: 01761) since June 2018, a director of Beijing Sanyuan Foods Co., Ltd (SSE: 600429) since March 2015 and a director of Dian Diagnostics Group Co., Ltd (SSEL 300244) from May 2010 to February 2019. Mr. Chen previously served on the board of directors of Maxigen Biotech Inc. (TWSE: 1783) from September 2015 until November 2017. In addition, Mr. Chen is the chairman of the China Medical Pharmaceutical Material Association, a vice president of the China Pharmaceutical Innovation and Research Development Association, the chairman of the Shanghai BioPharmaceutical Industry Association and the vice council of the Shanghai Society of Genetics. Mr. Chen is a member of the 13th Shanghai Standing Committee of the Chinese People’s Political Consultative Conference and was a member of the 12th Shanghai Standing Committee of the same conference. In 2018, Mr. Chen was awarded “Shanghai Excellent Constructor of Socialism with Chinese Characteristics from Non-Public Sector” and “Shanghai Outstanding Entrepreneur.” Mr. Chen obtained a Bachelor’s degree in genetics from Fudan University in 1993 and an EMBA degree from China Europe International Business School in 2005.

Shan Fu, Director


Mr. Shan Fu is a managing partner, a joint chief executive officer, and the Greater China chief executive officer of Vivo Capital, an investment firm that invests in the biotechnology and healthcare sectors. He also serves as director of Sinovac Biotech CO., Ltd (NASDAQ: SVA) since July 2018. Between June 2008 and October 2013, Mr. Fu worked as a senior managing director in the Beijing branch of Blackstone. Mr. Fu obtained a Master’s degree in history and a Bachelor’s degree in history, both from Peking University in Beijing, in 1991 and 1988, respectively.

David Zeng, Director


Mr. David Zeng leads the business operation of New Frontier Health as Chief Operations Officer, he is also the Managing Director of New Frontier Group. Prior to joining New Frontier, Mr. Zeng was a Senior Associate at Blackstone's Private Equity Group in Hong Kong. At Blackstone, he executed a number of investments across multiple industries in China, including the take-private of Global Sources Limited (one of world's largest electronics exhibition operators) and the buyout of Shya Hsin Packaging (one of world's largest color cosmetics plastic packagers). Mr. Zeng was also actively involved in the operations of Blackstone portfolio companies. He was most recently the interim-CFO and Executive Director of Shya Hsin Packaging and led a number of key operational initiatives. Prior to joining Blackstone, Mr. Zeng was a member of the Mergers & Acquisitions Group at Barclays in Hong Kong. Mr. Zeng obtained a bachelor's degree in Economics from Pomona College.

Edward Leong Che-hung, Independent Director


Dr. Edward Leong has been a director of New Frontier Health since the closing of its initial public offering. Dr. Leong is one of the most respected medical professionals and public health administrators in Asia, having actively engaged in public services and in various influential public roles during his career. He was a member of the Legislative Council of Hong Kong, representing the medical constituency from 1988 to 2000. In 2002, Dr. Leong was appointed as the chairman of the Hong Kong Hospital Authority where he was involved in drawing up the blueprint for Hospital Authority, taking special responsibility for Medical Service Development. Subsequently, Dr. Leong served as a non-official member of the Executive Council HKSAR from 2005 to 2012. He was chairman of the Hong Kong University Council until 2015 and spearheaded the commissioning of The University of Hong Kong - Shenzhen Hospital in Shenzhen during his term. Dr. Leong also served as the chairman of the Standard Working Hours Committee from 2013 to 2016. His other former public positions include the Chairman of the Elderly Commission HKSAR, Chairman of Hong Kong AIDS Foundation and the Elder Academy Development Foundation. Dr. Leong was awarded the Gold Bauhinia Star in 2001 and the Grand Bauhinia Medal in 2010.

Dr. Leong is a medical doctor and has been in private practice specializing in urology for several decades. After graduating from the University of Hong Kong in 1962, Dr. Leong worked in the Department of Surgery in Hong Kong University for 14 years. In addition to training medical students, Dr. Leong also conducted cutting-edge research in his specialist field of urology. His major research contributions include experiments and the human use of the stomach for bladder replacement and urinary diversion. Dr. Leong was appointed hunterian Professor by the Royal College of Surgeons of England in 1975. He was the first Hong Kong-born Chinese doctor to have received this accolade.

Frederick Ma Si-hang, Independent Director


Mr. Frederick Ma has been a director of New Frontier Health since the closing of its initial public offering. He is currently an independent non-executive director of FWD Group and a director of Husky Energy Inc. Professor Ma was previously the non-executive chairman of the MTR Corporation. Professor Ma was previously an independent non-executive director of Agricultural Bank of China Limited, Aluminum Corporation of China Limited, Hutchison Port Holdings Management Pte. Limited and China Resources Land Limited, and also a non-executive director of China Mobile Communications Corporation and COFCO Corporation. He was a member of the Managing Board at Kowloon-Canton Railway Corporation and a director of Airport Authority Hong Kong and the Hong Kong Mortgage Corporation Limited.

Professor Ma was previously the Secretary for Financial Services and the Treasury of the Hong Kong Special Administrative Region (HKSAR) Government from 2002 to 2007. Professor Ma held the position of Secretary for Commerce and Economic Development of the HKSAR Government from 2007 to 2008. He is currently a non-official member of the HKSAR Government Chief Executive’s Council of Advisers on Innovation and Strategic Development, a member of the International Advisory Council of China Investment Corporation, and the Global Advisory Council of Bank of America. Professor Ma was awarded the Gold Bauhinia Star medal in 2009 and was appointed a Justice of the Peace in 2010.

Besides his corporate and government positions, Professor Ma has also take various roles in multiple universities in Asia. In 2008, Professor Ma took up an honorary professorship at the School of Economics and Finance at the University of Hong Kong. In 2013, he was also appointed an Honorary Professor of Business Administration at the Chinese University of Hong Kong. He is currently the Council Chairman of The Education University of Hong Kong and has been a Professor of Finance Practice at The Hong Kong Polytechnic University since 2012.

Lawrence Chia, Independent Director


Mr. Lawrence Chia has been a director and the Chairman of the Audit Committee of New Frontier Health since March 31, 2020. He is currently the CEO of the Samling Group of Companies, which has businesses in automobiles, properties, timber, infrastructure, oil palm, oil, and gas, with operations in a number of countries globally. Prior to joining Samling, Lawrence was previously the CEO of Deloitte China, and was on the Deloitte Touche Tohmatsu Limited (DTTL) Executive Committee based in New York and the DTTL Asia Pacific Executive Committee based in Hong Kong. He also serves as an Independent Non-Executive Director of BC Technology Group Limited, a publicly listed company on the Hong Kong Stock Exchange. Mr. Lawrence is a Chartered Accountant of the Institute of Chartered Accountants in England and Wales and a member of the Hong Kong Institute of Certified Public Accountants.